Overview
NICE is unable to make a recommendation on lisocabtagene maraleucel (Breyanzi) after 1 systemic treatment in adults when a stem cell transplant is unsuitable. This is because the company did not provide an evidence submission.
Last reviewed: 23 July 2025
Next review: We will review this decision if the company decides to make a submission.